News: Almirall, S.A. (ALM.MC)

ALM.MC on Madrid SE C.A.T.S.

8.78EUR
3:53am EST
Price Change (% chg)

€-0.01 (-0.11%)
Prev Close
€8.79
Open
€8.82
Day's High
€8.82
Day's Low
€8.76
Volume
13,459
Avg. Vol
343,102
52-wk High
€9.99
52-wk Low
€5.34

view news for:
Select another date:

Wed, Nov 25 2009

UPDATE 1-GW Pharma posts FY profit

* Says Bayer to pay 10 mln stg after UK approval of Sativex

Continue Reading

UPDATE 1-Almirall says to announce lung drug data Q1 2010

* Short-term Phase II study of Eklira vs tiotropium positive

UPDATE 1-Almirall to file for COPD drug in EU; shares rise

* Share price jumps over 4 percent (Adds details, share reaction, comment)

Cannabis chemicals may help fight prostate cancer

LONDON, Aug 19 (Reuters) - Chemicals in cannabis have been found to stop prostate cancer cells from growing in the laboratory, suggesting that cannabis-based medicines could one day help fight the disease, scientists said on Wednesday.

Cannabis medicine maker GW lures U.S. investor

LONDON (Reuters) - GW Pharmaceuticals won a significant endorsement for its cannabis-based medicines on Thursday as U.S. investor Great Point Partners bought a multi-million pound stake in the company, sending GW shares sharply higher.

UPDATE 3-UK cannabis medicine maker GW lures U.S. investor

(Recasts, adds byline, updates shares, writes through)

REFILE-UPDATE 2-GW says others likely to follow Great Point

(Corrects spelling of "endorsement" in ninth paragraph, adds dropped word "which" in seventh paragraph and changes share price move in fifth bullet point to "almost 12 percent")

Spanish stocks - Factors to watch on Thursday

MADRID, July 30 (Reuters) - The following Spanish stocks may be affected by newspaper reports and other factors on Thursday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy:

UPDATE 1-Almirall gets FDA approval for migraine drug

MADRID, June 3 (Reuters) - Spanish pharmaceutical firm Almirall on Wednesday said its Almotriptan migraine drug had gained U.S. Food and Drug Administration approval for adolescents.

Almirall gets FDA approval for migraine drug

MADRID, June 3 (Reuters) - Spanish pharmaceutical firm Almirall on Wednesday said its Almotriptan migraine drug had gained U.S. Food and Drug Administration approval for adolescents.

Select another date:

Market Views

Press Releases

view news for: